Protagonist Therapeutics, Inc. Total Debt 2014–2025
Protagonist Therapeutics, Inc. reported $0 of total debt (short- plus long-term borrowings) for fiscal 2025.
| Fiscal year | Total Debt | Change (YoY) |
|---|---|---|
| FY 2025 | $0 | — |
| FY 2024 | $0 | — |
| FY 2023 | $0 | — |
| FY 2022 | $0 | — |
| FY 2021 | $0 | — |
| FY 2020 | $0 | -100.0% |
| FY 2019 | $9.79M | — |
| FY 2018 | $0 | — |
| FY 2017 | $0 | — |
| FY 2016 | $0 | — |
| FY 2015 | $0 | — |
| FY 2014 | $0 | — |
Source: Protagonist Therapeutics, Inc. SEC filings — balance sheet (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open PTGX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Protagonist Therapeutics, Inc. reported $0 of total debt (short- plus long-term borrowings) for fiscal 2025. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Protagonist Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeProtagonist Therapeutics, Inc. — frequently asked questions
What is Protagonist Therapeutics, Inc.'s total debt (short- plus long-term borrowings)?
Protagonist Therapeutics, Inc. (PTGX) reported total debt (short- plus long-term borrowings) of $0 for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Protagonist Therapeutics, Inc.'s official SEC filings (balance sheet (10-K)), refreshed nightly. Not investment advice.
More PTGX financial history
Full PTGX fundamentals page → · Analyze total debt (short- plus long-term borrowings) with a free tool → · All 1,500+ companies →